Search for more clinical trials
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Conditions
Pseudomyxoma Peritonei. - Colorectal Carcinoma. - Ovarian Carcinoma. - Mesothelioma.
Conditions: official terms
Carcinoma - Mesothelioma - Ovarian Neoplasms - Pseudomyxoma Peritonei
Conditions: Keywords
Peritoneal carcinomatosis, Peritoneal surface malignancy, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, CRS, HIPEC, Prognostic biomarker, Predictive biomarker
Study Type
Observational [Patient Registry]
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Intervention
Name: Observational study.
Type: Other
Overall Status
Recruiting
Summary
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).
Detailed Description
The handling of patients with PSM involves multimodal and multidisciplinary treatment strategies such as CRS, the removal of all macroscopically detectable tumor, and HIPEC, instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease. The treatment is challenging and complex and associated with significant morbidity. Only patients with limited disease will benefit from the treatment, and better methods for patient selection are needed. The project group has a unique opportunity to address key questions because of acquired experience, an exceptional biobank and institutional database and novel animal models established at the Norwegian Radium Hospital.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:
- age > 18 years
- confirmed diagnosis of peritoneal surface malignancy
- candidate for CRS-HIPEC
- written informed consent
Exclusion Criteria:
- none
Approximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.
- age > 18 years
- confirmed diagnosis of peritoneal surface malignancy
- candidate for CRS-HIPEC
- written informed consent
Exclusion Criteria:
- none
Approximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.
Location
The Norwegian Radium Hospital
Oslo, Norway
Status: Recruiting
Contact: Kjersti Flatmark, MD PhD - +47 22 78 18 73 - Kjersti.Flatmark@rr-research.no
Start Date
September 2009
Completion Date
January 2023
Sponsors
Oslo University Hospital
Source
Oslo University Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page